SPI Pharma Statement- COVID-19

31 Mar 2020

COVID-19

We are constantly monitoring developments regarding the coronavirus/COVID-19 outbreak and we continue to follow local government and World Health Organization (WHO) advice relevant to our global network of sites.

Safeguarding the health and wellbeing of our employees, their families, and our communities, while continuing to support our customers by supplying pharmaceutical ingredients, is our priority.

Across the SPI Pharma business, our operations continue to follow our safety and GMP protocols and we are strictly following the WHO guidelines and local governmental regulations. Our employees have been fully trained on additional precautions. We have taken measures to ensure business continuity and mitigate the risk of the virus impacting our operations, supply chains, and customers who rely on us to help them responsibly produce pharmaceutical products. This planning is helping us support our teams across our facilities and ensure that we are operating safely, and our supply remains sound.

We are applying recommended guidance to ensure our employees’ safety as well as adequate product supply meeting our customers’ demand. We will continue to partner with and support our customers during this challenging period.                  

 

Best regards,

 

Jeanne Thoma

President and CEO

SPI Pharma Inc.